The MAD cohort also saw adverse events such as hair loss and reductions in hemoglobin and neutrophil counts. These side ...

Celldex has a strong cash position with a runway of 13-14 quarters, bolstered by a $424 million secondary offering in March 2024. Learn more on CLDX stock here.

Dr Sermed Mezher, a GP in the UK, explained how a certain feeling in the cold months could be a sign of a potentially ...

The closely watched chronic spontaneous urticaria (CSU, or hives) space chalked more early stage KIT inhibitor data as Third Harmonic Bio Inc. rolled out results from the phase I single and multiple ...

Third Harmonic Bio, Inc. (NASDAQ:THRD) revealed results from its Phase 1 single and multiple ascending dose (SAD/MAD) trial ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

If your legs itch whenever you head out into the cold, it could be a sign of a health condition that can be life-threatening ...

If your legs or other parts of your body itch when exposed to cold temperatures, it could be a sign of a health condition - ...

Q4 2024 Earnings Call Transcript February 13, 2025 Blueprint Medicines Corporation misses on earnings expectations. Reported ...

Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of ...

THB335 Phase 1 data support advancement into Phase 2 clinical trial in chronic spontaneous urticaria (CSU)Company initiating process to leverage ...